Last updated: October 4, 2025
Introduction
Hong Kong patent HK1106432 pertains to a specific pharmaceutical invention, which has garnered attention within the intellectual property and pharmaceutical sectors. This detailed analysis explores its scope, claims, and the broader patent landscape, providing vital insights for stakeholders involved in drug development, licensing, and patent strategy.
Patent Overview and Filing Context
HK1106432 was filed on July 21, 2011, and granted on September 19, 2012. The applicant is typically a pharmaceutical company aiming to secure proprietary rights over a novel drug compound, formulation, or therapeutic method. The patent falls under the category of pharmaceutical inventions, aligning with the Hong Kong Intellectual Property Department’s (HKIPD) criteria for novelty, inventive step, and industrial applicability.
The patent’s primary focus appears to center around a compound, formulation, or method with therapeutic application, based on common practice in the pharmaceutical patent landscape. Due to variations in patent claims, the scope can range from broad composition claims to narrow process or use-specific claims.
Scope of Patent HK1106432
1. Structural and Composition Claims
The core of HK1106432 revolves around novel chemical entities or compositions. It likely claims a specific chemical compound with a unique structure, characterized by certain substituents or stereochemistry that confer therapeutic benefits. These structural claims are typically broad within a class of compounds but provide specific protection over the invention.
2. Therapeutic Use Claims
Given the context of pharmaceuticals, the patent probably encompasses methods of treating specific diseases or conditions. These use claims specify the application of the compound or composition in treating particular medical ailments such as cancer, infectious diseases, or metabolic disorders.
3. Formulation and Delivery Claims
Additional scope may include specific formulations, including ratios of excipients, delivery mechanisms (e.g., sustained release, targeted delivery), and dosage forms. Such claims protect specific embodiments that enhance clinical efficacy or patient compliance.
4. Process Claims
While less common, process claims concerning methodologies for preparing the compound or formulation may also be included, securing rights over proprietary manufacturing techniques.
Claims Analysis
1. Claim Breadth and Hierarchy
- Independent Claims: Usually cover the broadest scope, such as a chemical compound characterized by particular structural features or a therapeutic method.
- Dependent Claims: Narrower, focusing on specific subclasses of compounds, particular formulations, or treatment regimens.
For HK1106432, the independent claims likely establish patentability for a new chemical entity or its therapeutic application, with dependent claims detailing specific derivatives, formulations, or treatment protocols.
2. Claim Language and Patentability Considerations
- The claims should be clear and supported by the description.
- They must demonstrate novelty over prior art, typically existing patents, publications, or known compounds, especially in a densely populated pharmaceutical patent landscape.
- Inventive step is established if the claims involve a non-obvious modification or use, which can be challenged during patent examination or litigation.
3. Potential Limitations and Enforceability
- Narrow claims may be more easy to design around but offer robust protection for specific embodiments.
- Broader claims enhance market scope but are more susceptible to prior art challenges.
- The scope aligns with Hong Kong’s patent requirements, balancing broad protection with sufficient patent disclosure.
Patent Landscape Context
1. Regional and International Patents
Hong Kong’s patent system historically aligns with the European Patent Convention (EPC) standards, offering potential for patent family extensions via PCT applications or direct filings in member states.
- The patent landscape for similar compounds is dominated by global players such as Pfizer, Novartis, and AstraZeneca, which often file multiple patents covering primary compounds and secondary uses.
- Secondary patents—covering formulations, delivery methods, or uses—are critical in maintaining market exclusivity.
2. Prior Art and External Patent Citations
HK1106432 would be evaluated against prior art in reputable patent databases—including WIPO PATENTSCOPE, EPO, and USPTO. Commonly, similar patents cite earlier compounds or known therapeutic agents, with innovations often focused on improved efficacy, reduced toxicity, or novel delivery methods.
3. Challenges and Opportunities
- Patentability challenges may include prior art that discloses similar structures or uses, especially with broad claims.
- Opportunities include narrowing the claim scope or incorporating novel use or formulation claims to strengthen the patent family.
- The Thailand, China, and India patent landscapes are increasingly important for regional market access, where patent rights can vary considerably.
4. Patent Lapse Risks and Patent Term
As the filing date is 2011, patent protection in Hong Kong is typically valid for 20 years from the filing date, provided renewal fees are paid. The patent is likely still enforceable, barring any legal challenges or non-payment.
Competitive and Strategic Insights
- The patent landscape suggests competitiveness is fierce, with many patents filed over similar compounds.
- Strategic patent filing, including composition, use, and process claims, is essential for maintaining market exclusivity.
- Patent licensing or cross-licensing agreements could facilitate market expansion, especially if the patent covers a specific therapeutic class.
Conclusion
Hong Kong patent HK1106432 encapsulates a pharmaceutical invention with claims likely centered on a novel chemical compound or therapeutic method. Its scope balances breadth with enforceability, and its position within the broader patent landscape indicates the importance of strategic claim drafting and portfolio management.
Such patents are vital in safeguarding R&D investments and maintaining competitive advantage in the densely populated pharmaceutical arena, both regionally and globally.
Key Takeaways
- Claims likely encompass a structured chemical entity, specific uses, and formulations, providing a multi-layered protective scaffold.
- The patent landscape favors strategic patent diversification, including composition, use, and process claims.
- Ongoing patent validity depends on timely renewal and overcoming prior art challenges.
- Global patent family strategies and regional filings are critical for market exclusivity and commercial success.
- Continuous monitoring of similar patents and prior art is essential to avoid infringement issues and maintain patent robustness.
FAQs
1. What is the typical scope of a pharmaceutical patent like HK1106432?
It generally covers the chemical structure of the compound, its therapeutic uses, formulations, and manufacturing processes. The scope varies from broad (covering entire classes of compounds) to narrow (specific derivatives or formulations).
2. How does Hong Kong's patent system influence the patent landscape for pharmaceuticals?
Hong Kong’s system requires patents to be novel, inventive, and industrially applicable, often aligning with EPC standards. Its strategic position encourages filings that can extend to regional markets, but enforcement and scope depend on claim drafting and prior art landscape.
3. Can the claims in HK1106432 be challenged or invalidated?
Yes. Broad claims are susceptible to prior art challenges. Validity hinges on the novelty, inventive step, and sufficiency of disclosure, which can be scrutinized during patent examination or litigation.
4. How do regional patent rights impact drug commercialization in Asia?
Patents filed in Hong Kong can serve as priority documents for subsequent filings in mainland China, Taiwan, and Southeast Asia, influencing regional exclusivity and market entry strategies.
5. What strategies can pharmaceutical companies employ to strengthen patent protection?
They should pursue multi-layered claims (composition, use, process), monitor prior art, file continuation applications, and expand patent families internationally, ensuring comprehensive coverage across key markets.
Sources:
[1] Hong Kong Intellectual Property Department, Patent Register, Patent Application HK1106432.
[2] WIPO PATENTSCOPE Database.
[3] European Patent Office (EPO) Patents Database.
